Glenmark Pharmaceuticals has reported results for second quarter ended September 30, 2012.
The company has reported over four-fold jump in its net profit at Rs 137.33 crore for the quarter ended September 30, 2012 as compared to Rs 31.46 crore for the same quarter in the previous year. Total income from operations has increased by 49.63% at Rs 593.13 crore for quarter under review as compared to Rs 396.40 crore for the quarter ended September 30, 2011.
On consolidated basis, the company has posted about three-fold jump in its net profit after tax, minority interest and share of profit of associates at Rs 156.75 crore for the quarter ended September 30, 2012 as compared to Rs 56.58 crore for the same quarter in the previous year. Total income has increased by 19.98% at Rs 1262.13 crore for quarter under review as compared to Rs 1051.91 crore for the quarter ended September 30, 2011.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1827.40 |
Dr. Reddys Lab | 1371.65 |
Cipla | 1488.00 |
Lupin | 2253.00 |
Zydus Lifesciences | 1008.50 |
View more.. |